



Investor News
Nr. 6/2013

Zealand to present at upcoming Bank of America Merrill Lynch Global Healthcare Conference in London

Copenhagen, Denmark, 5 September 2013 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, informs that the company will present at the upcoming Bank of America Merrill Lynch Global Healthcare Conference, which takes place on 11 – 13 September in London.

Date and time of presentation: **Wednesday 11 September 2013 at 13.00 BST**

Presenter: **David Solomon, President and Chief Executive Officer**

In the presentation, David Solomon will give an update on the status and outlook for the main assets in Zealand’s portfolio of products and pipeline drugs.

Please note that no new financial or other material new information relating to the company will be disclosed at the above listed conference.

For further information, please contact:

Hanne Leth Hillman, Vice President, Investor Relations & Corporate Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com



About Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the invention, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company's focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia[®]) is approved in Europe and Japan and under regulatory review in a large number of other countries globally, including in the US (NDA submission accepted in Feb 2013).

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: www.zealandpharma.com.

 @ZealandPharma